Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas.

The goal of this research was to elucidate the relationship between WHO 2016 molecular classifications of newly diagnosed, nonenhancing lower grade gliomas (LrGG), tissue sample histopathology, and magnetic resonance (MR) parameters derived from diffusion, perfusion, and 1H spectroscopic imaging from the tissue sample locations and the entire tumor. A total of 135 patients were scanned prior to initial surgery, with tumor cellularity scores obtained from 88 image-guided tissue samples. MR parameters were obtained from corresponding sample locations, and histograms of normalized MR parameters within the T2 fluid-attenuated inversion recovery lesion were analyzed in order to evaluate differences between subgroups. For tissue samples, higher tumor scores were related to increased normalized apparent diffusion coefficient (nADC), lower fractional anisotropy (nFA), lower cerebral blood volume (nCBV), higher choline (nCho), and lower N-acetylaspartate (nNAA). Within the T2 lesion, higher tumor grade was associated with higher nADC, lower nFA, and higher Cho to NAA index. Pathological analysis confirmed that diffusion and metabolic parameters increased and perfusion decreased with tumor cellularity. This information can be used to select targets for tissue sampling and to aid in making decisions about treating residual disease.

Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism.

Magnetic resonance imaging (MRI) is the neuroimaging method of choice for the noninvasive monitoring of patients with brain tumors due to the enormous amount of information it yields regarding the morphologic features of the lesion and surrounding parenchyma. Over the past decade, proton magnetic resonance spectroscopy (1H-MRS), which uses the same technology as MRI and can be performed during a routine clinical imaging examination, has been used to glean information about the metabolic status of the brain. Accurate interpretation of 1H-MRS data from individual patients requires an understanding of the various techniques for acquiring the data, the physiologic basis of the metabolic signatures obtained from different types of tumors, and the specificity of the technique. This review covers the basic physics of 1H-MRS, the spectral and physiological characteristics of the metabolites that are typically measured in various types of brain tumors, and the clinical utility of 1H-MRS with respect to diagnosis, therapeutic planning, and the assessment of response to treatment.